Palvella Therapeutics (PVLA) News Today $23.93 -0.51 (-2.09%) As of 04/15/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period FY2025 Earnings Forecast for PVLA Issued By Chardan CapitalApril 15 at 1:52 AM | americanbankingnews.comWhat is Chardan Capital's Estimate for PVLA FY2025 Earnings?Palvella Therapeutics (NASDAQ:PVLA - Free Report) - Research analysts at Chardan Capital issued their FY2025 earnings estimates for shares of Palvella Therapeutics in a report released on Wednesday, April 9th. Chardan Capital analyst G. Livshits anticipates that the company will post earnings perApril 15 at 1:31 AM | marketbeat.comPalvella Therapeutics Showcases Progress on QTORIN Rapamycin Gel for Rare Genetic DisorderApril 12, 2025 | msn.comPalvella Therapeutics (NASDAQ:PVLA) Now Covered by Analysts at Chardan CapitalApril 12, 2025 | americanbankingnews.comPalvella Therapeutics announces data on QTORIN rapamycinApril 11, 2025 | markets.businessinsider.comPalvella Therapeutics (NASDAQ:PVLA) Coverage Initiated at Chardan CapitalChardan Capital initiated coverage on shares of Palvella Therapeutics in a report on Wednesday. They issued a "buy" rating and a $50.00 target price on the stock.April 11, 2025 | marketbeat.comPalvella Therapeutics Announces QTORIN™ Rapamycin 3.9% Anhydrous Gel for the Treatment of Microcystic Lymphatic Malformations Featured in Oral Presentation by Amy Paller, M.S., M.D., Chair of Dermatology at Northwestern University's Feinberg School of Medicine, at the 15th World Congress of Pediatric DermatologyApril 11, 2025 | globenewswire.comGeorge M. Jenkins Purchases 2,500 Shares of Palvella Therapeutics (NASDAQ:PVLA) StockApril 11, 2025 | insidertrades.comDirector Makes Bold Move with Major Stock Purchase in Palvella Therapeutics!April 10, 2025 | tipranks.comPalvella Therapeutics initiated with a Buy at ChardanApril 9, 2025 | markets.businessinsider.comChardan Capital Initiates Coverage of Palvella Therapeutics (PVLA) with Buy RecommendationApril 9, 2025 | msn.comADAR1 Capital Management LLC Invests $1.74 Million in Palvella Therapeutics (NASDAQ:PVLA)ADAR1 Capital Management LLC bought a new stake in shares of Palvella Therapeutics (NASDAQ:PVLA - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 144,641 shares of the company's stock, valued at approximately $1,7April 9, 2025 | marketbeat.comQ1 EPS Forecast for Palvella Therapeutics Lowered by AnalystPalvella Therapeutics (NASDAQ:PVLA - Free Report) - Equities researchers at HC Wainwright cut their Q1 2025 earnings per share (EPS) estimates for shares of Palvella Therapeutics in a report issued on Tuesday, April 1st. HC Wainwright analyst A. Fein now anticipates that the company will post earApril 6, 2025 | marketbeat.comPalvella CEO to Present at Healthcare Innovation ConferenceApril 6, 2025 | msn.comHC Wainwright Issues Pessimistic Outlook for PVLA EarningsApril 6, 2025 | americanbankingnews.comPalvella Therapeutics to Present at the Jones Healthcare and Technology Innovation ConferenceApril 4, 2025 | gurufocus.comPalvella Therapeutics Announces Late-Breaking Presentation at Global Pediatric Dermatology CongressApril 2, 2025 | msn.comPalvella Therapeutics price target raised to $53 from $39 at CanaccordApril 2, 2025 | markets.businessinsider.comPalvella Therapeutics (PVLA) Receives a Buy from ScotiabankApril 2, 2025 | markets.businessinsider.comPalvella Therapeutics Reports 2024 Financial Results and Advances Rare Disease PipelineApril 2, 2025 | msn.comPalvella Therapeutics (NASDAQ:PVLA) Earns Buy Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $38.00 target price on shares of Palvella Therapeutics in a report on Tuesday.April 2, 2025 | marketbeat.comPalvella Therapeutics Announces Late-Breaking Oral Presentation at the 15th World Congress of Pediatric DermatologyApril 2, 2025 | globenewswire.comIs Palvella Therapeutics Inc. (PVLA) the Best Performing NASDAQ Stock So Far in 2025?April 1, 2025 | insidermonkey.comPalvella Therapeutics Inc (PVLA) Q4 2024 Earnings Call Highlights: Navigating Financial ...April 1, 2025 | gurufocus.comPalvella Therapeutics reports FY24 EPS ($7.83), consensus ($3.01)April 1, 2025 | markets.businessinsider.comPalvella Therapeutics price target raised to $70 from $30 at Cantor FitzgeraldApril 1, 2025 | markets.businessinsider.comQ4 2024 Palvella Therapeutics Inc Earnings Call TranscriptApril 1, 2025 | gurufocus.comPalvella Therapeutics Inc Reports 2024 Financial Results: Net Loss of $7. ...March 31, 2025 | gurufocus.comPalvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate UpdateMarch 31, 2025 | gurufocus.comPalvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate UpdateMarch 31, 2025 | globenewswire.comIs Palvella Therapeutics (PVLA) the Best Performing Stock So Far in 2025?March 27, 2025 | msn.comStifel Nicolaus Begins Coverage on Palvella Therapeutics (NASDAQ:PVLA)Stifel Nicolaus began coverage on shares of Palvella Therapeutics in a research report on Wednesday. They set a "buy" rating and a $45.00 price target for the company.March 27, 2025 | marketbeat.comPalvella Therapeutics (NASDAQ:PVLA) Upgraded by Jones Trading to Strong-Buy RatingJones Trading raised Palvella Therapeutics to a "strong-buy" rating in a research note on Monday.March 27, 2025 | marketbeat.comStifel Initiates Coverage of Palvella Therapeutics (PVLA) with Buy RecommendationMarch 27, 2025 | msn.comPalvella Therapeutics (NASDAQ:PVLA) Given Consensus Rating of "Buy" by BrokeragesPalvella Therapeutics (NASDAQ:PVLA - Get Free Report) has received an average rating of "Buy" from the six ratings firms that are presently covering the firm, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation. The average 12-month price targeMarch 26, 2025 | marketbeat.comPalvella Therapeutics (NASDAQ:PVLA) Now Covered by Analysts at Jones TradingJones Trading initiated coverage on shares of Palvella Therapeutics in a research note on Tuesday. They issued a "buy" rating and a $45.00 price target for the company.March 26, 2025 | marketbeat.comJones Trading Initiates Coverage of Palvella Therapeutics (PVLA) with Buy RecommendationMarch 26, 2025 | msn.comPalvella Therapeutics (PVLA) to Release Quarterly Earnings on MondayPalvella Therapeutics (NASDAQ:PVLA) will be releasing earnings before the market opens on Monday, March 31, Financial Modeling Prep reports.March 25, 2025 | marketbeat.comPalvella Therapeutics (PVLA) Projected to Post Earnings on ThursdayPalvella Therapeutics (NASDAQ:PVLA) will be releasing earnings before the market opens on Thursday, March 27, Financial Modeling Prep reports.March 20, 2025 | marketbeat.comScotiabank Sticks to Its Buy Rating for Palvella Therapeutics (PVLA)March 19, 2025 | markets.businessinsider.comPalvella Therapeutics to Announce 2024 Financial Results and Host Investor Call on March 31, 2025March 19, 2025 | msn.comPalvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025March 18, 2025 | globenewswire.comIndividual investors who hold 41% of Palvella Therapeutics, Inc. (NASDAQ:PVLA) gained 12%, insiders profited as wellMarch 16, 2025 | finance.yahoo.comPavella - Undiscovered Biotechnology StockMarch 12, 2025 | msn.comScotiabank Initiates Coverage of Palvella Therapeutics (PVLA) with Sector Outperform RecommendationMarch 8, 2025 | msn.comPalvella Therapeutics (NASDAQ:PVLA) Coverage Initiated at ScotiabankScotiabank began coverage on shares of Palvella Therapeutics in a research report on Friday. They set a "sector outperform" rating and a $50.00 target price on the stock.March 8, 2025 | marketbeat.comBML Capital Management LLC Makes New Investment in Palvella Therapeutics (NASDAQ:PVLA)BML Capital Management LLC bought a new position in Palvella Therapeutics (NASDAQ:PVLA - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 42,130 shares of the company's stockMarch 8, 2025 | marketbeat.comPalvella Therapeutics initiated with an Outperform at ScotiabankMarch 7, 2025 | markets.businessinsider.comPositive Outlook on Palvella Therapeutics: Buy Rating Backed by Promising QTORIN Rapamycin PotentialMarch 7, 2025 | tipranks.comWhy These 15 Biotech Stocks Are Skyrocketing So Far In 2025March 3, 2025 | insidermonkey.com Remove Ads Get Palvella Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PVLA and its competitors with MarketBeat's FREE daily newsletter. Email Address PVLA Media Mentions By Week PVLA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PVLA News Sentiment▼0.900.79▲Average Medical News Sentiment PVLA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PVLA Articles This Week▼174▲PVLA Articles Average Week Remove Ads Get Palvella Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PVLA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CALT News Today OCUL News Today ARDX News Today WVE News Today PCRX News Today EVO News Today INVA News Today AUPH News Today DYN News Today SNDX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PVLA) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredTrump 2028 could be a “bonanza” for investorsAs you may have heard, Donald Trump is planning to run for a THIRD term in 2028. Recently he told NBC news ...Paradigm Press | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Palvella Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Palvella Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
